Tag Archive for: drug development

Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company

/in

San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]

Read more

BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum

/in

2026 marks BIO-Europe’s evolution from partnering-led conference into the continent’s largest biopharma strategy forum Expands its program to convene the full C-suite of strategy leaders, building on its commitment to open dialogue and constructive partnerships Seven integrated tracks and high-impact plenary sessions to address the forces reshaping the global biopharma industry London, UK – 18 […]

Read more

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

/in

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Read more

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

/in

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]

Read more
© Optimum Strategic Communications.